Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/effect-of-therapeutic-drug-monitoring-vs-standard-therapy-during-9TD1wOGcae
References (50)
-
N. Casteele, R. Khanna, B. Levesque, L. Stitt, G. Zou, Sharat Singh, S. Lockton, S. Hauenstein, L. Ohrmund, G. Greenberg, P. Rutgeerts, A. Gils, W. Sandborn, S. Vermeire, B. Feagan (2014)
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's diseaseGut, 64
-
L. Kleinman, E. Norton (2009)
What's the Risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression.Health services research, 44 1
-
J Torres, S Bonovas, G Doherty (2020)
ECCO guidelines on therapeutics in Crohn’s disease: medical treatmentJ Crohns Colitis, 14
-
K. Jørgensen, Inge Olsen, G. Goll, M. Lorentzen, NOR-SWITCH group (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trialThe Lancet, 389
-
England (2019)
1540Arthritis Care Res (Hoboken), 71
-
Joseph Feuerstein, Geoffrey Nguyen, Sonia Kupfer, Y. Falck-Ytter, Siddharth Singh (2017)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.Gastroenterology, 153 3
-
Torres (2020)
4J Crohns Colitis, 14
-
Berth-Jones (2006)
707Br J Dermatol, 155
-
J. Curtis, A. Ogdie, M. George (2021)
Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases.JAMA, 325 17
-
Takeuchi (2009)
478Mod Rheumatol, 19
-
D. Turner, A. Ricciuto, Ayanna Lewis, F. D’Amico, J. Dhaliwal, A. Griffiths, D. Bettenworth, W. Sandborn, B. Sands, W. Reinisch, J. Schölmerich, W. Bemelman, S. Danese, J. Mary, D. Rubin, J. Colombel, L. Peyrin-Biroulet, I. Dotan, M. Abreu, A. Dignass (2020)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.Gastroenterology
-
A. Mourad, R. Gniadecki (2020)
Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-AnalysisFrontiers in Medicine, 7
-
E. St.clair, C. Wagner, A. Fasanmade, Benjamin Wang, T. Schaible, A. Kavanaugh, E. Keystone (2002)
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.Arthritis and rheumatism, 46 6
-
Prevoo (1995)
44Arthritis Rheum, 38
-
I. Markusse, L. Dirven, A. Gerards, J. Groenendael, H. Ronday, P. Kerstens, W. Lems, T. Huizinga, C. Allaart (2015)
Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt studyArthritis Research & Therapy, 17
-
Kleinman (2009)
288Health Serv Res, 44
-
R. Harvey, J. Bradshaw (1980)
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 315
-
S. Fernandes, S. Bernardo, C. Simões, A. Gonçalves, A. Valente, C. Baldaia, P. Santos, L. Correia, R. Marinho (2019)
Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.Inflammatory bowel diseases
-
M. Prevoo, M. Hof, H. Kuper, M. Leeuwen, L. Putte, P. Riel (1995)
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.Arthritis and rheumatism, 38 1
-
J. Lewis, S. Chuai, Lisa Nessel, G. Lichtenstein, F. Aberra, J. Ellenberg (2008)
Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 14
-
T. Takeuchi, N. Miyasaka, Kazuhiko Inoue, T. Abe, T. Koike (2009)
Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING studyModern Rheumatology, 19
-
G. Roda, B. Jharap, N. Neeraj, J. Colombel (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and ManagementClinical and Translational Gastroenterology, 7
-
M. Movahedi, E. Hepworth, R. Mirza, A. Cesta, M. Larché, C. Bombardier (2020)
Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort.Seminars in arthritis and rheumatism, 50 5
-
U. Mrowietz, K. Kragballe, K. Reich, P. Spuls, C. Griffiths, A. Nast, J. Franke, C. Antoniou, P. Arenberger, F. Balieva, M. Bylaitė, O. Correia, E. Daudén, P. Gisondi, L. Iversen, L. Kemény, M. Lahfa, T. Nijsten, T. Rantanen, A. Reich, T. Rosenbach, S. Segaert, Catherine Smith, T. Talme, B. Volc-Platzer, N. Yawalkar (2010)
Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 303
-
C. Lukas, R. Landewé, J. Sieper, M. Dougados, John Davis, J. Braun, S. Linden, D. Heijde (2008)
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 68
-
C. Flurey, M. Morris, P. Richards, R. Hughes, S. Hewlett (2013)
It’s like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimesRheumatology (Oxford, England), 53
-
(2013)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.JAMA, 310 20
-
G. D'Haens, S. Vermeire, G. Lambrecht, F. Baert, P. Bossuyt, B. Pariente, A. Buisson, Y. Bouhnik, J. Filippi, Janneke Woude, P. Hootegem, J. Moreau, E. Louis, D. Franchimont, M. Vos, F. Mana, L. Peyrin-Biroulet, H. Brixi, M. Allez, P. Caenepeel, A. Aubourg, B. Oldenburg, M. Pierik, A. Gils, S. Chevret, D. Laharie (2018)
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.Gastroenterology, 154 5
-
B. England, Benedict Tiong, M. Bergman, J. Curtis, S. Kazi, T. Mikuls, J. O'dell, V. Ranganath, A. Limanni, L. Suter, K. Michaud (2019)
2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity MeasuresArthritis Care & Research, 71
-
J. Maneiro, E. Salgado, J. Gómez-Reino (2013)
Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.JAMA internal medicine, 173 15
-
S. Syversen, G. Goll, K. Jørgensen, Inge Olsen, Ø. Sandanger, J. Gehin, D. Warren, J. Sexton, C. Mork, J. Jahnsen, T. Kvien, N. Bolstad, E. Haavardsholm (2019)
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)Trials, 21
-
S. Vermeire, S. Schreiber, W. Sandborn, Cécile Dubois, P. Rutgeerts (2010)
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 8 4
-
O. Adedokun, W. Sandborn, B. Feagan, P. Rutgeerts, Zhenhua Xu, C. Marano, J. Johanns, Honghui Zhou, H. Davis, F. Cornillie, W. Reinisch (2014)
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.Gastroenterology, 147 6
-
Extended Report -
G. D'Haens, W. Sandborn, B. Feagan, K. Geboes, S. Hanauer, E. Irvine, M. Lémann, P. Marteau, P. Rutgeerts, J. Schölmerich, L. Sutherland (2007)
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.Gastroenterology, 132 2
-
K. Papamichael, Karen Chachu, Ravy Vajravelu, B. Vaughn, Josephine Ni, M. Osterman, A. Cheifetz (2017)
Improved Long‐term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of InfliximabClinical Gastroenterology & Hepatology, 15
-
J. Berth‐Jones, K. Grotzinger, C. Rainville, B. Pham, J. Huang, S. Daly, M. Herdman, P. Firth, K. Hotchkiss (2006)
A study examining inter‐ and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global AssessmentBritish Journal of Dermatology, 155
-
N. Mitrev, N. Casteele, C. Seow, J. Andrews, S. Connor, G. Moore, M. Barclay, J. Begun, R. Bryant, W. Chan, C. Corte, S. Ghaly, D. Lemberg, V. Kariyawasam, P. Lewindon, Jennifer Martin, R. Mountifield, G. Radford-Smith, P. Slobodian, M. Sparrow, C. Toong, D. Langenberg, M. Ward, R. Leong (2017)
Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseasesAlimentary Pharmacology & Therapeutics, 46
-
K. Papamichael, A. Cheifetz, G. Melmed, P. Irving, N. Casteele, P. Kozuch, L. Raffals, L. Baidoo, B. Bressler, S. Devlin, Jennifer Jones, G. Kaplan, M. Sparrow, F. Velayos, T. Ullman, C. Siegel (2019)
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
-
T. Fredriksson, U. Pettersson (1978)
Severe psoriasis--oral therapy with a new retinoid.Dermatologica, 157 4
-
St Clair (2002)
1451Arthritis Rheum, 46
-
C. Lamb, C. Lamb, N. Kennedy, T. Raine, P. Hendy, P. Hendy, Philip Smith, J. Limdi, J. Limdi, B. Hayee, BuʼHussain Hayee, M. Lomer, M. Lomer, G. Parkes, G. Parkes, C. Selinger, C. Selinger, K. Barrett, R. Davies, Cathy Bennett, Stuart Gittens, M. Dunlop, M. Dunlop, O. Faiz, A. Fraser, V. Garrick, Paul Johnston, M. Parkes, J. Sanderson, J. Sanderson, H. Terry, D. Gaya, D. Gaya, T. Iqbal, T. Iqbal, S. Taylor, S. Taylor, Melissa Smith, Melissa Smith, M. Brookes, R. Hansen, A. Hawthorne (2019)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adultsGut, 68
-
S. Syversen, G. Goll, K. Jørgensen, Ø. Sandanger, J. Sexton, Inge Olsen, J. Gehin, D. Warren, M. Brun, R. Klaasen, L. Karlsen, G. Noraberg, C. Zettel, M. Ljoså, A. Haugen, Rune Njålla, T. Bruun, K. Seeberg, B. Michelsen, E. Strand, S. Skorpe, I. Blomgren, Y. Bragnes, C. Dotterud, Turid Thune, C. Ystrøm, R. Torp, P. Mielnik, C. Mork, T. Kvien, J. Jahnsen, N. Bolstad, E. Haavardsholm (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.JAMA, 325 17
-
J. Smolen, R. Landewé, J. Bijlsma, G. Burmester, M. Dougados, A. Kerschbaumer, I. McInnes, A. Sepriano, R. Vollenhoven, M. Wit, D. Aletaha, M. Aringer, J. Askling, A. Balsa, M. Boers, A. Broeder, M. Buch, F. Buttgereit, R. Caporali, M. Cardiel, D. Cock, C. Codreanu, M. Cutolo, C. Edwards, Y. Eijk-Hustings, P. Emery, A. Finckh, L. Gossec, J. Gottenberg, M. Hetland, T. Huizinga, Marios Koloumas, Zhanguo Li, X. Mariette, U. Müller-Ladner, E. Mysler, J. Silva, G. Poór, J. Pope, A. Rubbert-Roth, A. Ruyssen-Witrand, K. Saag, A. Strangfeld, T. Takeuchi, M. Voshaar, R. Westhovens, D. Heijde (2020)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateAnnals of the Rheumatic Diseases, 79
-
Dana Berg, J. Colombel, R. Ungaro (2019)
The Role of Early Biologic Therapy in Inflammatory Bowel Disease.Inflammatory bowel diseases
-
P Machado, R Landewé, E Lie (2011)
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scoresAnn Rheum Dis, 70
-
K. Papamichael, T. Stappen, N. Casteele, A. Gils, T. Billiet, S. Tops, K. Claes, G. Assche, P. Rutgeerts, S. Vermeire, M. Ferrante (2016)
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 14 4
-
Machado (2011)
47Ann Rheum Dis, 70
-
M. Adamina, S. Bonovas, T. Raine, A. Spinelli, J. Warusavitarne, A. Armuzzi, O. Bachmann, P. Bager, L. Biancone, B. Bokemeyer, P. Bossuyt, J. Burisch, P. Collins, G. Doherty, A. El‐Hussuna, P. Ellul, G. Fiorino, C. Frei-Lanter, F. Furfaro, C. Gingert, P. Gionchetti, J. Gisbert, F. Gomollón, Marien Lorenzo, H. Gordon, T. Hlavatý, P. Juillerat, K. Katsanos, U. Kopylov, E. Krustiņš, T. Kucharzik, T. Lytras, C. Maaser, F. Magro, J. Marshall, P. Myrelid, G. Pellino, I. Rosa, J. Sabino, E. Savarino, L. Stassen, J. Torres, M. Uzzan, S. Vavricka, B. Verstockt, O. Zmora (2019)
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.Journal of Crohn's & colitis
-
N. Casteele, M. Ferrante, G. Assche, V. Ballet, G. Compernolle, K. Steen, S. Simoens, P. Rutgeerts, A. Gils, S. Vermeire (2015)
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.Gastroenterology, 148 7
- Publisher
- American Medical Association
- Copyright
- Copyright 2021 American Medical Association. All Rights Reserved.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.2021.21316
- Publisher site
- See Article on Publisher Site
Abstract
Key PointsQuestionAmong patients with immune-mediated inflammatory diseases undergoing maintenance therapy with infliximab, is proactive therapeutic drug monitoring (TDM) more effective than standard therapy to sustain disease control without disease worsening? FindingsIn this randomized clinical trial that included 458 patients, the proportion of patients with sustained disease control without disease worsening during 52 weeks of follow-up was 74% in the TDM group and 56% in the standard therapy group, a statistically significant difference. MeaningProactive TDM compared with treatment without TDM during maintenance infliximab therapy was more likely to lead to sustained disease control over 52 weeks for patients with immune-mediated inflammatory diseases.
Journal
JAMA – American Medical Association
Published: Dec 21, 2021